Impact Factor 2020: 1.226 (@Clarivate Analytics)
5-Year Impact Factor: 2.285 (@Clarivate Analytics)
Immediacy Index: 2.645
  • Users Online: 443
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2019  |  Volume : 12  |  Issue : 14  |  Page : 32-40

Recombinant human calcineurin B inhibits orthotopic hepatocellular carcinoma xenograt growth in mice by promoting apoptosis


1 Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Provincial Center for Drug Safety Evaluation and Research, Hainan Medical University, Haikou 571199, P.R. China
2 Tumor Institute, the First Affiliated Hospital of Hainan Medical University, Haikou 570102, P.R. China
3 Public Research Laboratory, Hainan Medical University, Haikou 571199, P.R. China
4 Department of Internal Medicine, the Second Affiliated Hospital of Hainan Medical University, Haikou 570203, P.R. China
5 Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Provincial Center for Drug Safety Evaluation and Research, Hainan Medical University, Haikou; Tumor Institute, the First Affiliated Hospital of Hainan Medical University, Haikou 570102; Research Unit of Island Emergency Medicine, Chinese Academy of Medical Sciences, Hainan Medical University, Haikou 571199, P.R. China

Correspondence Address:
Shao-Jiang Zheng
Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Provincial Center for Drug Safety Evaluation and Research, Hainan Medical University, 3 Xueyuan Road, Longhua District, Haikou, 571199
P.R. China
Shen-Hong Gu
Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Provincial Center for Drug Safety Evaluation and Research, Hainan Medical University, 3 Xueyuan Road, Longhua District, Haikou, 571199
P.R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.271978

Get Permissions

Objective: To explore the effects of recombinant human calcineurin B (rhCNB) on hepatocellular carcinoma in mice. Methods: An in vivo mouse model with hepatocellular carcinoma was established, and the mice were randomized into the rhCNB, positive control and vehicle treatments groups. Tumor growth was assessed via bioluminescence using a small animal imaging system. Relative tumor proliferation rate and tumor growth inhibition were calculated. The expression of p53 and caspase-9 proteins in tumors were detected by immunohistochemistry. In vitro, flow cytometry was used to quantify the cell-cycle stages and rate of apoptosis. Western blotting and quantitative real-time PCR assays were used to evaluate the effects of rhCNB on protein and gene expression of CDK1, cyclin B1, p53 and caspase-9. Results: rhCNB at the higher dose significantly reduced tumor growth in vivo and caused tumor cell apoptosis in vitro. The rhCNB at the higher dose was as effective as cisplatin, and was safer. Conclusions: rhCNB has potent pro-apoptotic effects on tumor cells in vivo and in vitro and is well tolerated in vivo.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1132    
    Printed51    
    Emailed0    
    PDF Downloaded134    
    Comments [Add]    

Recommend this journal